Unlocking the Immune System to Attack Cancer    


Neon Therapeutics (NASDAQ: NTGN) is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.


Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

November 16, 2018
Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe

November 12, 2018
Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

November 9, 2018
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Read More News

Associated Team Members

Robert Kamen, Ph.D.
Venture Partner

Cary Pfeffer, M.D.
Partner

Robert Tepper, M.D.
Partner

Stephen Sherwin, M.D.
Venture Partner

Ton Schumacher, Ph.D.
Venture Partner